ZNF165 antibody - middle region (ARP35689_P050)
- Known as:
- ZNF165 (anti-) - middle region (ARP35689_P050)
- Catalog number:
- arp35689_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ZNF165 antibody - middle region (ARP35689_P050)
Related genes to: ZNF165 antibody - middle region (ARP35689_P050)
- Gene:
- ZNF165 NIH gene
- Name:
- zinc finger protein 165
- Previous symbol:
- -
- Synonyms:
- ZSCAN7, CT53
- Chromosome:
- 6p22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-02-17
- Date modifiied:
- 2016-10-05
Related products to: ZNF165 antibody - middle region (ARP35689_P050)
Related articles to: ZNF165 antibody - middle region (ARP35689_P050)
- Pediatric gliomas, comprising both low-grade (LGGs) and high-grade gliomas (HGGs), exhibit significant molecular and clinical heterogeneity. While LGGs generally have a favorable prognosis, HGGs are associated with poor long-term survival despite aggressive treatment. Advances in molecular profiling have enabled targeted therapies, but treatment resistance and tumor heterogeneity remain major challenges. The integration of artificial intelligence (AI) and transcriptomic data holds promise for refining prognostic models and guiding personalized treatment strategies, yet its application in pediatric gliomas remains underexplored. - Source: PubMed
Publication date: 2026/03/09
Li GanglongPei FuyuWang Weizhen - The role of ZNF165 in only a few tumors has been reported. ZNF165 plays an important role in liver cancer, gastric cancer, and breast cancer, especially in regulating the immune microenvironment, promoting tumor cell proliferation and migration, and serving as a potential target for immunotherapy. - Source: PubMed
Lyu GuizhenLi Dongbing - Mesenchymal stem cells (MSCs) have been identified to have a unique migratory pattern toward tumor sites across diverse cancer types, playing a crucial role in cancer progression, treatment resistance, and immunosuppression. This study aims to formulate a prognostic model focused on MSC-associated markers to efficiently predict the clinical outcomes and responses to therapy in individuals with bladder cancer (BC). Clinical and transcriptome profiling data were extracted from The Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-BLCA) and GSE31684 databases. Systematic quantification of MSC prevalences and stromal indices was undertaken, culminating in the discernment of genes correlated with stromal MSCs following a thorough application of weighted gene coexpression network analysis techniques. Subsequently, an exhaustive risk signature pertinent to MSC was formulated by amalgamating methods from univariate and Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression models. Drugs targeting genes associated with MSCs were screened using molecular docking. The prognostic model for MSC incorporated five critical genes: ZNF165, matrix remodeling-associated 7 (MXRA7), CEMIP, ADP-ribosylation factor-like 4C (ARL4C), and cerebral endothelial cell adhesion molecule (CERCAM). In the case of BC patients, stratification was performed into discrete risk categories, utilizing the median MSC risk score as a criterion. It was striking that those classified within the high-MSC-risk bracket demonstrated correlations with unfavorable prognostic implications. Enhanced responsiveness to immunotherapy in low-MSC-risk patients was delineated compared to their high-MSC-risk counterparts. A heightened receptivity was noted toward particular chemotherapy drugs, encompassing gemcitabine, vincristine, paclitaxel, gefitinib, and sorafenib, within this high-risk group. Conversely, a superior reaction to cisplatin was distinctly evident among those marked by low MSC scores. The results of molecular docking demonstrated that kaempferol exhibited favorable docking with ZNF165, quercetin exhibited favorable docking with MXRA7, mairin exhibited favorable docking with CEMIP, and limonin diosphenol exhibited favorable docking with ARL4C. The five-gene MSC prognostic model demonstrates substantial efficacy in prognosticating clinical outcomes and gauging responsiveness to chemotherapy and immunotherapy regimens. The genes ZNF165, MXRA7, CEMIP, ARL4C, and CERCAM are underscored as promising candidates warranting further exploration for anti-MSC therapeutic strategies, thereby offering novel insights for personalized treatment approaches in BC. - Source: PubMed
Publication date: 2024/11/15
Yang EnguangJi LuhuaZhang XinyuJing SuoshiLi PanWang HanzhangZhang LuyangZhang YuanfengYang LiTian JunqiangWang Zhiping - Crohn's disease (CD) is a chronic idiopathic inflammatory bowel disease affecting the entire gastrointestinal tract from the mouth to the anus. These patients often experience a period of symptomatic relapse and remission. A 20 - 30% symptomatic recurrence rate is reported in the first year after surgery, with a 10% increase each subsequent year. Thus, surgery is done only to relieve symptoms and not for the complete cure of the disease. The determinants and the genetic factors of this disease recurrence are also not well-defined. Therefore, enhanced diagnostic efficiency and prognostic outcome are critical for confronting CD recurrence. - Source: PubMed
Rajalingam ArunaSekar KanagarajGanjiwale Anjali - The prognosis of bladder cancer (BLCA) and response to immune checkpoint inhibitors (ICIs) are determined by multiple factors. Existed biomarkers for predicting the effect of immunotherapy cannot accurately predict the response of BLCA patients to ICIs. - Source: PubMed
Publication date: 2023/05/30
Xue YuwenZhao GuanghuiPu XiaoxinJiao Fangdong